Yini esikwaziyo mayelana nePropecia nomdlavuza wesicathulo ? Ucwaningo olubonakala lubonisa inzuzo engabavikelayo yamadoda athathe i-Propecia ashintshe ngempela lokho odokotela batusa kumadoda enengozi enkulu yokuthuthukisa umdlavuza we-prostate?
Ucwaningo nge-Propecia ne-Cancer Prostate
Ubufakazi bufikile ukuthi iPropia (i-finasteride) - izidakamizwa ezisetshenziselwa ukuphatha i-pattern baldness yamadoda - ingasiza ekuvikeleni umdlavuza wesi-prostate kubantu abengozi enkulu yokuthuthukisa lesi sifo.
Ezinye izifundo ziye zabonisa nokuthi i-Propecia (noma izidakamizwa ezifanayo) zingase ziphuze ukuqala komdlavuza wesi-prostate kwamanye amadoda.
Kwabe sekucatshangwe isikhathi eside ukuthi i-Propecia noma izidakamizwa ezifanayo zingase zinikeze izinzuzo ezithile zokuvikela ukuthi zisebenza kanjani emzimbeni. I-Propecia ingenye yeklasi yezidakamizwa eziphikisana nemiphumela ye- testosterone emzimbeni. I-Testosterone iyaziwa ukuthi ingenye yezimbangela zokukhula komdlavuza we-prostate.
Okubalulekile ukukhumbula mayelana nalezi zifundo ukuthi yizo zokuqala kuphela. Ukwengeza, amanye amadoda asethathe i-Propecia noma izidakamizwa ezifanayo emzamweni wokuvimbela noma wokulibazisa umdlavuza we-prostate nazo zihlangabezane nemiphumela emibi kakhulu.
Yiziphi ezinye zezinto ezibaluleke kunazo zonke ezithinta imiphumela yeProtepia?
Ngenxa yokuthi i-Propecia iphikisana nemiphumela ye-testosterone emzimbeni, imiphumela emibi yocansi ingathuthuka. Esicwaningweni esisodwa, cishe abantu abangu-1/3 bayeka ukusebenza kweProteka ngenxa yezizathu ezingezona umdlavuza.
Ngaphezu kwalokho, ucwaningo luye lwabonisa ukuthi izinga le- PSA lamadoda ku-Propecia lingabhalwa njengeliphansi, okwenza ukuthi amantombazane alahleke.
Ingozi ye-propecia ne-Prostate Cancer
Okubaluleke kakhulu, ezinye izifundo zibonise ukuthi nakuba amadoda athatha i-Propecia angase abe nethuba elincanyana lokuthuthukisa umdlavuza wesifo sofuba, lezo zomshukela ezithuthuka zivame ukuba ziphakeme kakhulu futhi zihlukumezeke ngokulingana.
I-Propecia ne-Prostate Cancer Ukusinda
Nakuba izifo zomdlavuza we-prostate wehla cishe kubantu abasebenzisa i-Propecia, ukuhlola akukafaneli kubonise ukuthi imithi inomthelela ekusindeni, kungaba ngumdlavuza wesifo sofuba noma ngenxa yezimbangela zokufa. Isizathu singase sibe ukuthi ekucwaningeni kuze kube yimanje kube khona ukufa okumbalwa kakhulu, okwenza kube nzima ukuthi lezi zibalo zihlolwe, noma kungenzeka ukuthi ngenkathi kunciphisa isigameko akukwenzi umehluko ekusindeni. Enye indlela kungenzeka ukuthi i-Propecia inciphisa izigameko zegciwane eliphansi, kepha ayinayo umphumela ebangeni eliphezulu (okungenzeka ukuthi libulale).
Ingabe Odokotela Bathanda Ngokwemvelo Propecia for Prostate Cancer Prevention?
Namuhla, odokotela abambalwa kakhulu bancoma iPropia kubantu abaningi abanomdlavuza wesifo sofuba. Lokhu ikakhulukazi ngenxa yemiphumela emibi yangezinye izikhathi ezingabangela, kodwa futhi ngenxa yokuthi kungenzeka ukuthi amadoda athatha i-Propecia noma izidakamizwa ezifanayo azokuthuthukisa ukwelashwa okunamandla (njengoba ezinye izifundo ziphakanyisiwe).
Ngokuvamile, uma i-Propecia iyisidakamizwa onesithakazelo ekuthathweni kwezintambo zokuvimbela umdlavuza we-prostate, khuluma nodokotela wakho futhi uqiniseke ukuthi ubuyekeze zonke izinzuzo nezindleko zesinqumo.
Imithombo:
U-Azzouni, F., noJ. Mohler. Indima ye-5a-reductase inhibitors ekuvimbeleni umdlavuza we-prostate nokuphathwa. Urology . 79 (6): 1197-20.
Hoque, A. et al. Umphumela we-finasteride ku-serum androstenedione kanye nengozi yomdlavuza wesi-prostate ngaphakathi kwecala lokuvimbela umdlavuza we-prostate: umphumela wokuhlukana kwezifo eziphezulu nokuphansi. Urology . 2015. 85 (3): 616-20.
UMurtola, T. et al. Ukuvuvukala emathisini e-benign prostate kanye nomdlavuza wesi-prostate engxenyeni ye-finasteride ye-Prostate Cancer Prevention Trial. I-Epidemiology ye-Cancer Epidemiology Biomarkers and Prevention .
I-National Cancer Institute. I-Prostate Cancer Prevention - abaqeqeshiwe bezempilo (PDQ).
Thompson, I. et al. Ithonya le-finasteride ekuthuthukiseni umdlavuza wesi-prostate. I-New England Journal of Medicine . 2003. 349 (3): 215-34.